Drug intelligence / Profile preview

ASP3700

Development stage: Discontinued
Lead developer: Astellas Pharma
Modality: Small Molecules
Administration: Oral

Overview

ASP3700 is an oral small molecule drug that was developed by Astellas Pharma for the treatment of osteoarthritis, specifically targeting pain associated with the disease. The compound reached phase 1 clinical trials, where its safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) were evaluated in healthy volunteers. The precise mechanism of action remains undefined or unreported. Development was discontinued after phase 1 trials[1][2][4][5].

Beyond the preview

Go deeper on ASP3700.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ASP3700.

Explore the full profile